# US 2019/0194746 A1 · Nucleic acid oligomer for rna hybrid formation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0194746 A1
- Document ID: US20190194746A1
- Status: Published application
- Kind: A1
- Application number: 16/083,347
- Filed: 2017-03-09
- Published: 2019-06-27
- Earliest claimed: 2016-03-09
- Assignees: Tokyo University of Science Foundation
- Applicants: Tokyo University of Science Foundation
- Inventors: Takeshi Wada; Reijiro Yoshino; Rintaro Hara; Yohei Nukaga
- Web page: https://patentgrep.com/patent/US20190194746A1

## CPC

- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6853: using modified primers or templates
- C12Q 2527/101: Temperature
- C12Q 2527/107: Temperature of melting, i.e. Tm
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A nucleic acid oligomer for RNA hybrid formation, including a structure formed of from 3 to 50 continuous units of at least one unit of a nucleotide unit represented by the following General Formula (1) or a nucleotide unit represented by the following General Formula (2); and having a base length of from 8 bases to 50 bases: in which in the formulae, R1 represents a hydrogen atom, an alkoxy group, an alkenyloxy group, an acyloxy group, a trialkylsilyloxy group, or a halogenyl group, and, in the formulae, each Bs1 independently represents a pyrimidine base that may have a protecting group, a hydrogen atom bonded to a carbon atom at the 5-position of the pyrimidine base may be substituted with a group other than a hydrogen atom, in the formulae, each X independently represents S−Z+ or BH3—Z+, Z+ represents a counter cation, each R2 and R3 independently represents a hydrogen atom, or an alkyl group having from 1 to 10 carbon atoms, and R2 and R3 may be bonded to each other to form a ring.

## Claims

### Claim 1

A nucleic acid oligomer for RNA hybrid formation, comprising a structure formed of from 3 to 50 continuous units of at least one unit of a nucleotide unit represented by the following General Formula (1) or a nucleotide unit represented by the following General Formula (2), and having a base length of from 8 bases to 50 bases:
wherein, in General Formula (1), R1 represents a hydrogen atom, an alkoxy group, an alkenyloxy group, an acyloxy group, a trialkylsilyloxy group, or a halogenyl group; in General Formulae (1) and (2), each Bs1 independently represents a pyrimidine base that may have a protecting group, and a hydrogen atom bonded to a carbon atom at 5-position of the pyrimidine base is substituted with a propynyl group; and in General Formulae (1) and (2), each X independently represents S−Z+ or BH3—Z+, Z+ represents a counter cation, each R2 and R3 independently represents a hydrogen atom, or an alkyl group having from 1 to 10 carbon atoms, and R2 and R3 may be bonded to each other to form a ring.

### Claim 2 (depends on 1)

The nucleic acid oligomer for RNA hybrid formation according to claim 1, wherein, in General Formulae (1) and (2), Bs1 is a group represented by the following General Formulae (3) or (4):
wherein, in General Formula (3), R4 represents propynyl groupan and each of a carbonyl group and an amino group in General Formula (3) may have a protecting group; and in General Formula (4), R5 represents propynyl groupan, and each of a carbonyl group and an amino group in General Formula (4) may have a protecting group.

### Claim 3 (depends on 1)

The nucleic acid oligomer for RNA hybrid formation according to claim 1, wherein the nucleic acid oligomer for RNA hybrid formation has a base length of from 10 bases to 30 bases.

### Claim 4 (depends on 1)

The nucleic acid oligomer for RNA hybrid formation according to claim 1, wherein the nucleic acid oligomer for RNA hybrid formation comprises a structure formed of from 5 to 30 continuous units of at least one unit of the nucleotide unit represented by General Formula (1) or the nucleotide unit represented by General Formula (2).

### Claim at position 5

-6. (canceled)

### Claim 7 (depends on 1)

An agent for RNA hybrid formation comprising the nucleic acid oligomer for RNA hybrid formation according to claim 1.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

A method for forming an RNA hybrid comprising the nucleic acid oligomer for RNA hybrid formation according to claim 1.

### Claim 10

(canceled)
